---
title: "BioMarin Pharmaceutical Inc. (BMRN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BMRN.US.md"
symbol: "BMRN.US"
name: "BioMarin Pharmaceutical Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:40:57.369Z"
locales:
  - [en](https://longbridge.com/en/quote/BMRN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BMRN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BMRN.US.md)
---

# BioMarin Pharmaceutical Inc. (BMRN.US)

## Company Overview

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biomarin.com](https://www.biomarin.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.90% |  |
| Net Profit YoY | -48.70% |  |
| P/B Ratio | 1.55 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9599722290.76 |  |
| Revenue | 3242316000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.48% | C |
| Profit Margin | 8.29% | B |
| Gross Margin | 51.21% | B |
| Revenue YoY | 9.90% | B |
| Net Profit YoY | -48.70% | D |
| Total Assets YoY | 20.20% | A |
| Net Assets YoY | 7.23% | B |
| Cash Flow Margin | 325.31% | A |
| OCF YoY | 9.90% | B |
| Turnover | 0.41 | C |
| Gearing Ratio | 27.69% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioMarin Pharmaceutical Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.90%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.70%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.55",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9599722290.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3242316000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.48%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.29%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "51.21%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "9.90%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.70%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "20.20%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.23%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "325.31%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "9.90%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.69%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.72 | 49/386 | 29.85 | 20.93 | 17.11 |
| PB | 1.55 | 146/386 | 1.90 | 1.80 | 1.71 |
| PS (TTM) | 2.96 | 70/386 | 3.72 | 3.52 | 3.31 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 15 | 60% |
| Overweight | 4 | 16% |
| Hold | 6 | 24% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 49.81 |
| Highest Target | 120.00 |
| Lowest Target | 55.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BMRN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BMRN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BMRN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BMRN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**